SEC Form 3 · accession 0001628280-19-001773

Soliton, Inc. · SOLY

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — CEO, President · Director

Period of report

Feb 19, 2019

Accepted (ET)

Feb 22, 2019 · 5:01 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001548187

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	holding	—	—		—	263,440	D
Common Stock^F1	holding	—	—		—	212,500	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Option to purchase common stock (right to buy)^F2	$1.75	holding	—	—	—	—	Jun 18, 2028	Common Stock	725,000	—	D
Option to purchase common stock (right to buy)^F3	$1.75	holding	—	—	—	—	Feb 5, 2029	Common Stock	108,500	—	D
Warrant to purchase common stock (right to buy)	$1.75	holding	—	—	—	Oct 19, 2018	Oct 19, 2023	Common Stock	11,512	—	D
Warrant to purchase common stock (right to buy)	$1.75	holding	—	—	—	Oct 30, 2018	Oct 30, 2023	Common Stock	8,634	—	D
Warrant to purchase common stock (right to buy)	$1.75	holding	—	—	—	Nov 15, 2018	Nov 15, 2023	Common Stock	7,771	—	D

F1Represents 212,500 shares of common stock currently held by M.D. Anderson Cancer Center that were issued pursuant to Soliton, Incs license agreement with MD Anderson. As the inventor of the intellectual property licensed from MD Anderson, Dr. Capelli is entitled to 50% of the proceeds (after the recoupment of any costs associated therewith) from the sale by MD Anderson of the shares issued to the MD Anderson in connection with the license agreement. Notwithstanding Dr. Capelli pecuniary interest in the shares held by MD Anderson, Dr. Capelli has no right to vote or sell the shares held by MD Anderson.
F2The options set forth in this table vest in four equal annual installments beginning on the first anniversary of the issuance date, or June 18, 2018, subject to the grantee's continued service on each vesting date.
F3The options set forth in this table vest in four equal quarterly installments beginning on the issuance date, or February 5, 2019, subject to the grantee's continued service on each vesting date.